Abstract: The present disclosure discloses a recycling method of a ternary material micropowder, and use thereof. The recycling method includes: washing the ternary material micropowder with water, and adding a coating agent and an promotor; subjecting a resulting mixture to a reaction under heating and pressurization, and filtering to obtain a coated base material; subjecting the coated base material to sintering, adding an extracting agent to a resulting sintered material, and stirring and filtering to obtain a filter residue; and subjecting the filter residue to drying, sieving, and iron removal to obtain a ternary cathode material. In the present disclosure, the coating agent and the promotor are added to achieve high-pressure hydrothermal coating for the micropowder. The coating agent can optimize the storage performance of the material and increase the life of the material.

Abstract: Disclosed is a method for purifying a nickel-cobalt-manganese leaching solution.

Abstract: The invention belongs to the technical field of material synthesis, and discloses a nitrogen-doped hollow cobaltosic oxide and a preparation method and application thereof. A chemical formula of the nitrogen-doped hollow cobaltosic oxide is Co3O4—COF-T-D@C—N; and the COF-T-D is a covalent organic framework. Due to an open hollow structure, the nitrogen-doped hollow cobaltosic oxide of the invention has a large specific surface area, thus having a large contact area with an electrolyte, which is convenient for lithium ions to transport therein. The open hollow structure also prevents a volume effect from being generated during charging and discharging, and nitrogen is introduced for doping, so that granules can be gradually activated to increase the specific surface area and active sites, a discharge (cycle) stability of the material is improved, and a rate performance of the material is improved.

Abstract: The subject invention pertains to compositions and methods for treating neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis, epilepsy, stroke, alcohol withdrawal, progressive supranuclear palsy (PSP), Pick's disease (PiD), corticobasal degeneration (CBD), frontotemporal dementia or parkinsonism linked to chromosome 17 (FTDP-17). The methods of the subject invention further relate to methods of fermentation of bacterial cells and methods of tautomerization of the subject compounds.

Abstract: The subject invention pertains to compositions comprising albofungin and/or derivatives thereof, including, chloroalbofungin, 477-albo, 492-albo, 505-albo, 506-1-albo, 506-2-albo, 519-albo, and 562-albo. The subject invention further pertains to methods of treating a subject with HIV using albofungin and/or derivatives thereof, including, chloroalbofungin, 477-albo, 492-albo, 505-albo, 506-1-albo, 506-2-albo, 519-albo, and 562-albo.

Abstract: The subject invention pertains to compositions comprising albofungin and/or derivatives thereof, including, chloroalbofungin, 477-albo, 492-albo, 505-albo, 506-1-albo, 506-2-albo, 519-albo, and 562-albo. The subject invention further pertains to methods of treating a subject with HIV using albofungin and/or derivatives thereof, including, chloroalbofungin, 477-albo, 492-albo, 505-albo, 506-1-albo, 506-2-albo, 519-albo, and 562-albo.

Abstract: The subject invention pertains to compositions and methods for treating neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis, epilepsy, stroke, alcohol withdrawal, progressive supranuclear palsy (PSP), Pick's disease (PiD), corticobasal degeneration (CBD), frontotemporal dementia or parkinsonism linked to chromosome 17 (FTDP-17). The methods of the subject invention further relate to methods of fermentation of bacterial cells and methods of tautomerization of the subject compounds.

Abstract: Compositions of angiostatic agents for treating choroidal neovascularization resulting from ocular surgery or from trauma to ocular tissue and methods for their use are disclosed.

Abstract: Compositions of angiostatic agents for treating choroidal neovascularization resulting from ocular surgery or from trauma to ocular tissue and methods for their use are disclosed.